ZNF608

Summary

ZNF608 (zinc finger protein 608, HGNC:29238) is a protein-coding gene on chromosome 5q23.2, encoding Zinc finger protein 608 (Q9ULD9). Transcription factor, which represses ZNF609 transcription.

Predicted to enable zinc ion binding activity. Predicted to be involved in negative regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 57507 — RefSeq curated summary.

At a glance

• GWAS associations: 41
• Clinical variants (ClinVar): 186 total
• MANE Select transcript: NM_020747

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29238
Approved symbol	ZNF608
Name	zinc finger protein 608
Location	5q23.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1281, DKFZp434M098, NY-REN-36
Ensembl gene	ENSG00000168916
Ensembl biotype	protein_coding
OMIM	620972
Entrez	57507

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 4 protein_coding, 4 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000306315, ENST00000503896, ENST00000504926, ENST00000505686, ENST00000509799, ENST00000511308, ENST00000512940, ENST00000513985, ENST00000513986

RefSeq mRNA: 4 — MANE Select: NM_020747 NM_001385619, NM_001385620, NM_001385621, NM_020747

CCDS: CCDS34219

Canonical transcript exons

ENST00000513986 — 10 exons

Exon	Start	End
ENSE00002068555	124746195	124746639
ENSE00002075892	124744084	124745172
ENSE00003482666	124701014	124701269
ENSE00003490205	124646679	124649133
ENSE00003490382	124649610	124649697
ENSE00003508528	124639133	124639214
ENSE00003596018	124641252	124641405
ENSE00003643486	124643511	124643683
ENSE00003681967	124644244	124644661
ENSE00003916226	124636915	124637906

Expression profiles

Bgee: expression breadth ubiquitous, 241 present calls, max score 96.08.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.3863 / max 1727.4719, expressed in 1254 samples.

FANTOM5 promoters (16 alternative TSS)

Promoter ID	TPM avg	Samples expressed
63174	5.6205	984
63183	4.9307	887
63173	1.3510	486
63179	1.1985	380
63182	0.8769	313
63168	0.7582	401
63176	0.5934	261
63172	0.5839	238
63178	0.4610	196
63171	0.2977	167

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cardiac muscle of right atrium	UBERON:0003379	96.08	gold quality
embryo	UBERON:0000922	94.57	gold quality
ganglionic eminence	UBERON:0004023	94.57	gold quality
ventricular zone	UBERON:0003053	94.29	gold quality
corpus callosum	UBERON:0002336	92.77	gold quality
adrenal tissue	UBERON:0018303	91.74	gold quality
sural nerve	UBERON:0015488	88.41	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	87.95	gold quality
spinal cord	UBERON:0002240	87.70	gold quality
cerebellar vermis	UBERON:0004720	87.52	gold quality
right adrenal gland cortex	UBERON:0035827	86.71	gold quality
left adrenal gland cortex	UBERON:0035825	86.50	gold quality
left adrenal gland	UBERON:0001234	86.40	gold quality
adrenal cortex	UBERON:0001235	86.29	gold quality
adrenal gland	UBERON:0002369	86.24	gold quality
mucosa of stomach	UBERON:0001199	86.16	gold quality
right adrenal gland	UBERON:0001233	85.97	gold quality
cortical plate	UBERON:0005343	85.68	gold quality
right uterine tube	UBERON:0001302	85.63	gold quality
right lobe of thyroid gland	UBERON:0001119	85.58	gold quality
subthalamic nucleus	UBERON:0001906	85.53	gold quality
lateral globus pallidus	UBERON:0002476	85.34	gold quality
amygdala	UBERON:0001876	85.33	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	85.29	gold quality
right lung	UBERON:0002167	85.12	gold quality
cardiac atrium	UBERON:0002081	85.01	gold quality
upper lobe of left lung	UBERON:0008952	84.79	gold quality
duodenum	UBERON:0002114	84.78	gold quality
cerebellar cortex	UBERON:0002129	84.62	gold quality
right hemisphere of cerebellum	UBERON:0014890	84.60	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-93593	yes	14.67
E-ANND-3	yes	6.28
E-GEOD-83139	yes	5.05

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

184 targeting ZNF608, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-LET-7F-2-3P	99.98	70.98	2588

Literature-anchored findings (GeneRIF, showing 1)

• Data indicate RNA Binding Protein with Multiple Splicing (RBPMS), Regulator of Chromosome Condensation and POZ Domain Containing Protein 1 (RCBTB1), and Zinc Finger protein 608 (ZNF608) as miR-21-3p target genes. (PMID:27166999)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp608	ENSMUSG00000052713
rattus_norvegicus	Zfp608	ENSRNOG00000023197
drosophila_melanogaster	sbb	FBGN0285917

Paralogs (1): ZNF609 (ENSG00000180357)

Protein

Protein identifiers

Zinc finger protein 608 — Q9ULD9 (reviewed: Q9ULD9)

Alternative names: Renal carcinoma antigen NY-REN-36

All UniProt accessions (4): A0A0C4DGB8, A2RRB2, B3KPE6, Q9ULD9

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor, which represses ZNF609 transcription.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9ULD9-1	1	yes
Q9ULD9-2	2

RefSeq proteins (4): NP_001372548, NP_001372549, NP_001372550, NP_065798* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR040010	ZN608/ZN609	Family

UniProt features (62 total): compositionally biased region 22, region of interest 13, cross-link 12, modified residue 9, chain 1, zinc finger region 1, coiled-coil region 1, splice variant 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9ULD9-F1	44.80	0.03

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (21): 421, 424, 481, 493, 627, 782, 895, 964, 1098, 283, 880, 1118, 1176, 1182, 1199, 1216, 1234, 1250, 1292, 1310 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 219 (showing top): MODULE_169, SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_DN, GCGCTTT_MIR518B_MIR518C_MIR518D, BILD_HRAS_ONCOGENIC_SIGNATURE, AGCGCTT_MIR518F_MIR518E_MIR518A, CATTTCA_MIR203, AAACCAC_MIR140, ATTCTTT_MIR186, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, TGCCTTA_MIR124A, GAVIN_FOXP3_TARGETS_CLUSTER_P3, GAVIN_IL2_RESPONSIVE_FOXP3_TARGETS_UP, ZHENG_BOUND_BY_FOXP3, ZHENG_FOXP3_TARGETS_IN_T_LYMPHOCYTE_UP, ZHAN_MULTIPLE_MYELOMA_CD2_UP

GO Biological Process (2): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (2): zinc ion binding (GO:0008270), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
regulation of DNA-templated transcription	1
transition metal ion binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

658 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF608	TMEM160	Q9NX00	691
ZNF608	DNAJC27	Q9NZQ0	606
ZNF608	MTIF3	Q9H2K0	594
ZNF608	NUDT3	O95989	583
ZNF608	POC5	Q8NA72	575
ZNF608	QPCTL	Q9NXS2	571
ZNF608	GPRC5B	Q9NZH0	570
ZNF608	V9GXZ4	V9GXZ4	570
ZNF608	GRAMD2B	Q96HH9	546
ZNF608	SEC16B	Q96JE7	544
ZNF608	GNPDA2	Q8TDQ7	541
ZNF608	TNNI3K	Q59H18	541
ZNF608	ATN1	P54259	536
ZNF608	LINGO2	Q7L985	517
ZNF608	CADM2	Q8N3J6	507

IntAct

54 interactions, top by confidence:

A	B	Type	Score
HDAC1	CDK2AP1	psi-mi:“MI:0914”(association)	0.840
HDAC1	TNRC18	psi-mi:“MI:0914”(association)	0.790
MED23	MED19	psi-mi:“MI:2364”(proximity)	0.770
DYNLL1	BLTP3B	psi-mi:“MI:0914”(association)	0.730
HDAC1	ZNF609	psi-mi:“MI:0914”(association)	0.730
NFIC	NFIB	psi-mi:“MI:2364”(proximity)	0.690
DYNLL2	BLTP3B	psi-mi:“MI:0914”(association)	0.640
EN1	NFIB	psi-mi:“MI:2364”(proximity)	0.470
ZNF608	ATN1	psi-mi:“MI:0407”(direct interaction)	0.440
AUTS2	ZNF609	psi-mi:“MI:0914”(association)	0.350
WDR5	PHF20L1	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
SLC16A11	ESYT2	psi-mi:“MI:0914”(association)	0.350
RAF1	EIF3F	psi-mi:“MI:0914”(association)	0.350
AR	MED6	psi-mi:“MI:2364”(proximity)	0.270
RAVER1	KDM6A	psi-mi:“MI:2364”(proximity)	0.270
SOX7	NFIB	psi-mi:“MI:2364”(proximity)	0.270
TBXT	BCL9	psi-mi:“MI:2364”(proximity)	0.270
ERG	BCL9	psi-mi:“MI:2364”(proximity)	0.270
FEV	TAF4	psi-mi:“MI:2364”(proximity)	0.270
FOXI1	BCL9	psi-mi:“MI:2364”(proximity)	0.270
FOXL1	PGRMC1	psi-mi:“MI:2364”(proximity)	0.270
FOXQ1	ZNF609	psi-mi:“MI:2364”(proximity)	0.270
GATA2	BCL9	psi-mi:“MI:2364”(proximity)	0.270
HNF1B	BCL9	psi-mi:“MI:2364”(proximity)	0.270
HNF4A	TAF4	psi-mi:“MI:2364”(proximity)	0.270
IRF4	ARID1A	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (99): ZNF608 (Affinity Capture-MS), ZNF608 (Proximity Label-MS), ZNF608 (Affinity Capture-MS), ZNF608 (Affinity Capture-RNA), ZNF608 (Affinity Capture-MS), ZNF608 (Affinity Capture-MS), ZNF608 (Proximity Label-MS), ZNF608 (Affinity Capture-MS), ZNF608 (Affinity Capture-MS), ZNF608 (Proximity Label-MS), ZNF608 (Proximity Label-MS), ZNF608 (Affinity Capture-MS), ZNF608 (Affinity Capture-MS), KANSL3 (Affinity Capture-MS), ZNF608 (Affinity Capture-MS)

ESM2 similar proteins: A2A935, A5GFT6, A5PK23, A5X7A0, A7MB40, A7XYH5, A7XYH9, A7XYI6, A7XYJ6, A7XYQ1, E1BE02, E2R9X2, E7F888, F1LMN3, F6NSX9, O15265, O95402, P78312, Q03989, Q04891, Q0P5V2, Q15911, Q3U108, Q56A10, Q58FA4, Q5ZJ69, Q5ZM88, Q61329, Q62255, Q68FE9, Q6PJG2, Q6ZSZ6, Q76L83, Q7YR76, Q86V15, Q8BZ32, Q8BZ47, Q8CGI1, Q8K4J6, Q8R4I1

Diamond homologs: O15014, Q56A10, Q8BZ47, Q9ULD9, Q9UTH8, P32432, Q5RDF5, Q80ZQ5, Q86VZ6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 65 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Deactivation of the beta-catenin transactivating complex	5	25.3×	3e-04

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of transcription initiation by RNA polymerase II	5	21.6×	2e-04
somatic stem cell population maintenance	5	19.7×	3e-04
anatomical structure morphogenesis	8	17.7×	2e-06
transcription by RNA polymerase II	11	12.3×	3e-07
gene expression	7	8.9×	4e-04
chromatin remodeling	7	8.1×	7e-04
positive regulation of gene expression	9	5.5×	9e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

186 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	172
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1909 predictions. Top by Δscore:

Variant	Effect	Δscore
5:124639128:TTTA:T	donor_loss	1.0000
5:124639129:TTAC:T	donor_loss	1.0000
5:124639130:TA:T	donor_loss	1.0000
5:124639131:ACCT:A	donor_loss	1.0000
5:124639132:C:CA	donor_loss	1.0000
5:124639132:CCTT:C	donor_gain	1.0000
5:124641248:TGA:T	donor_loss	1.0000
5:124641249:GAC:G	donor_loss	1.0000
5:124641250:A:T	donor_loss	1.0000
5:124641251:C:CT	donor_loss	1.0000
5:124641401:ACAGG:A	acceptor_gain	1.0000
5:124641402:CAGG:C	acceptor_gain	1.0000
5:124641402:CAGGC:C	acceptor_gain	1.0000
5:124641403:AGG:A	acceptor_gain	1.0000
5:124641404:GG:G	acceptor_gain	1.0000
5:124641404:GGCT:G	acceptor_loss	1.0000
5:124641406:C:CC	acceptor_gain	1.0000
5:124641406:CTGCA:C	acceptor_loss	1.0000
5:124641407:T:C	acceptor_loss	1.0000
5:124643505:GCTTA:G	donor_loss	1.0000
5:124643506:CTTAC:C	donor_loss	1.0000
5:124643508:TA:T	donor_loss	1.0000
5:124643509:A:AC	donor_gain	1.0000
5:124643509:AC:A	donor_loss	1.0000
5:124643509:ACAG:A	donor_gain	1.0000
5:124643510:C:CT	donor_gain	1.0000
5:124643510:CA:C	donor_gain	1.0000
5:124643510:CAG:C	donor_gain	1.0000
5:124643510:CAGC:C	donor_gain	1.0000
5:124643510:CAGCA:C	donor_gain	1.0000

AlphaMissense

4655 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:124648663:T:G	Q574P	1.000
5:124648667:G:C	H573D	1.000
5:124648670:A:C	Y572D	1.000
5:124648670:A:G	Y572H	1.000
5:124648675:A:G	L570P	1.000
5:124648675:A:T	L570Q	1.000
5:124648678:C:A	G569V	1.000
5:124648678:C:T	G569D	1.000
5:124648679:C:A	G569C	1.000
5:124648679:C:G	G569R	1.000
5:124648689:C:A	K565N	1.000
5:124648689:C:G	K565N	1.000
5:124648693:T:C	Y564C	1.000
5:124648693:T:G	Y564S	1.000
5:124648694:A:C	Y564D	1.000
5:124648694:A:G	Y564H	1.000
5:124648694:A:T	Y564N	1.000
5:124648698:T:A	K562N	1.000
5:124648698:T:G	K562N	1.000
5:124648699:T:A	K562I	1.000
5:124648700:T:C	K562E	1.000
5:124648704:G:C	C560W	1.000
5:124648705:C:A	C560F	1.000
5:124648705:C:G	C560S	1.000
5:124648705:C:T	C560Y	1.000
5:124648706:A:C	C560G	1.000
5:124648706:A:G	C560R	1.000
5:124648706:A:T	C560S	1.000
5:124648719:A:C	C555W	1.000
5:124648720:C:A	C555F	1.000

dbSNP variants (sampled 300 via entrez): RS1000000396 (5:124745341 C>T), RS1000014558 (5:124689275 T>G), RS1000019869 (5:124700260 A>C), RS1000031178 (5:124715402 C>G,T), RS1000073354 (5:124699991 T>C), RS1000086213 (5:124651352 A>C), RS1000120564 (5:124665540 G>A), RS1000128118 (5:124709003 C>A,G), RS1000130255 (5:124748918 A>C), RS1000173083 (5:124650352 A>C,T), RS1000222691 (5:124706646 G>A), RS1000226098 (5:124658992 G>A), RS1000290327 (5:124702781 C>T), RS1000312462 (5:124670221 G>C), RS1000342179 (5:124669972 A>G)

Disease associations

OMIM: gene MIM:620972 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

41 associations (top):

Study	Trait	p-value
GCST000824_6	Erectile dysfunction and prostate cancer treatment	4.000000e-06
GCST000830_20	Body mass index	2.000000e-09
GCST001521_30	Subcutaneous adipose tissue	7.000000e-07
GCST002021_10	Body mass index	5.000000e-06
GCST002339_2	Type 2 diabetes (young onset) and obesity	6.000000e-06
GCST002690_5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	2.000000e-06
GCST002783_153	Body mass index	4.000000e-07
GCST002783_206	Body mass index	2.000000e-07
GCST003832_10	Asthma (childhood onset)	7.000000e-06
GCST003996_45	Monobrow	2.000000e-14
GCST004294_6	Nicotine dependence	2.000000e-06
GCST004485_45	Survival in pancreatic cancer	8.000000e-07
GCST004557_132	Body mass index	7.000000e-08
GCST004557_186	Body mass index	7.000000e-08
GCST004557_219	Body mass index	3.000000e-08
GCST004557_53	Body mass index	3.000000e-08
GCST004558_199	Body mass index (joint analysis main effects and physical activity interaction)	2.000000e-07
GCST004558_237	Body mass index (joint analysis main effects and physical activity interaction)	3.000000e-08
GCST004558_38	Body mass index (joint analysis main effects and physical activity interaction)	5.000000e-06
GCST004558_89	Body mass index (joint analysis main effects and physical activity interaction)	5.000000e-08
GCST004559_166	Body mass index in physically active individuals	2.000000e-08
GCST004559_188	Body mass index in physically active individuals	6.000000e-08
GCST004559_32	Body mass index in physically active individuals	2.000000e-06
GCST004559_83	Body mass index in physically active individuals	3.000000e-08
GCST004904_21	Body mass index	4.000000e-10
GCST004904_72	Body mass index	2.000000e-10
GCST007260_2	B6 vitamer levels (multivariate analysis)	8.000000e-07
GCST007324_5	Adventurousness	3.000000e-11
GCST007576_195	Chronotype	2.000000e-09
GCST008575_10	IgM levels	4.000000e-09

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0006796	very long-chain saturated fatty acid measurement
EFO:0007906	synophrys measurement
EFO:0000638	overall survival
EFO:0008002	physical activity measurement
EFO:0004621	vitamin B6 measurement
EFO:0008579	risk-taking behaviour
EFO:0008328	chronotype measurement
EFO:0010474	cystathionine measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004462	PR interval
EFO:0004980	appendicular lean mass
EFO:0009749	age at first sexual intercourse measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

60 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	4
trichostatin A	affects cotreatment, decreases expression	3
Air Pollutants	decreases expression, affects cotreatment, increases abundance	3
methylmercuric chloride	decreases expression, increases expression	2
bisphenol A	affects cotreatment, increases methylation, increases expression	2
sodium arsenite	decreases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Cyclosporine	decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
sotorasib	affects cotreatment, decreases expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
propionaldehyde	increases expression	1
pirinixic acid	increases activity, affects binding, decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	decreases expression	1
arsenite	increases methylation	1
sulforaphane	decreases expression	1
potassium chromate(VI)	decreases expression	1
nickel sulfate	decreases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
S-(1,2-dichlorovinyl)cysteine	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.